Victory Capital Management Inc. decreased its stake in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 18.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 178,501 shares of the company's stock after selling 39,338 shares during the quarter. Victory Capital Management Inc. owned approximately 0.28% of MoonLake Immunotherapeutics worth $9,666,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently bought and sold shares of MLTX. GSA Capital Partners LLP raised its position in shares of MoonLake Immunotherapeutics by 1.9% in the third quarter. GSA Capital Partners LLP now owns 22,127 shares of the company's stock worth $1,116,000 after acquiring an additional 403 shares during the period. US Bancorp DE acquired a new stake in MoonLake Immunotherapeutics in the third quarter valued at approximately $44,000. HighVista Strategies LLC increased its position in shares of MoonLake Immunotherapeutics by 3.1% in the third quarter. HighVista Strategies LLC now owns 43,541 shares of the company's stock valued at $2,195,000 after buying an additional 1,292 shares in the last quarter. Parkman Healthcare Partners LLC raised its stake in shares of MoonLake Immunotherapeutics by 1.6% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 102,813 shares of the company's stock worth $5,184,000 after buying an additional 1,589 shares during the period. Finally, Harbor Capital Advisors Inc. lifted its position in shares of MoonLake Immunotherapeutics by 2.8% during the 4th quarter. Harbor Capital Advisors Inc. now owns 79,648 shares of the company's stock valued at $4,313,000 after buying an additional 2,180 shares in the last quarter. 93.85% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
MLTX has been the subject of a number of research analyst reports. HC Wainwright restated a "buy" rating and set a $100.00 price objective on shares of MoonLake Immunotherapeutics in a research report on Thursday, February 27th. The Goldman Sachs Group reduced their price target on shares of MoonLake Immunotherapeutics from $82.00 to $73.00 and set a "buy" rating for the company in a research report on Thursday, February 27th. Finally, Needham & Company LLC raised their price target on shares of MoonLake Immunotherapeutics from $62.00 to $66.00 and gave the company a "buy" rating in a research note on Thursday, February 27th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, MoonLake Immunotherapeutics has a consensus rating of "Buy" and a consensus price target of $83.20.
View Our Latest Stock Analysis on MLTX
MoonLake Immunotherapeutics Stock Performance
Shares of NASDAQ MLTX traded up $0.12 during mid-day trading on Monday, reaching $38.67. The company's stock had a trading volume of 568,673 shares, compared to its average volume of 336,053. The stock has a market capitalization of $2.48 billion, a P/E ratio of -29.98 and a beta of 1.31. MoonLake Immunotherapeutics has a 1-year low of $36.52 and a 1-year high of $58.26. The stock has a 50-day moving average of $43.54 and a two-hundred day moving average of $48.27.
MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.09). Analysts predict that MoonLake Immunotherapeutics will post -1.79 EPS for the current fiscal year.
About MoonLake Immunotherapeutics
(
Free Report)
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.
Featured Articles
Before you consider MoonLake Immunotherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MoonLake Immunotherapeutics wasn't on the list.
While MoonLake Immunotherapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
